- Home
- OWLS vs RGNX Comparison
OWLS vs RGNX Comparison
Compare OWLS & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OWLS | RGNX |
|---|---|---|
| Founded | 2010 | 2008 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 795.4M | 661.2M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | OWLS | RGNX |
|---|---|---|
| Price | $7.72 | $12.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $30.29 |
| AVG Volume (30 Days) | 61.7K | ★ 586.6K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $7,569,630.00 | ★ $161,318,000.00 |
| Revenue This Year | N/A | $198.02 |
| Revenue Next Year | N/A | $2.67 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 18.29 | ★ 91.30 |
| 52 Week Low | $6.80 | $5.04 |
| 52 Week High | $90.00 | $13.93 |
Technical Indicators
Market Signals| Indicator | OWLS | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 55.58 |
| Support Level | N/A | $12.05 |
| Resistance Level | N/A | $13.80 |
| Average True Range (ATR) | 0.00 | 0.78 |
| MACD | 0.00 | 0.08 |
| Stochastic Oscillator | 0.00 | 60.41 |
Price Performance
Historical ComparisonAbout OWLS OBOOK Holdings Inc. Class A Common Shares
OBOOK Holdings Inc is focused on using blockchain technology to provide inventive solutions to customers in various sectors, including financial services, hospitality, and e-commerce. Through its e-commerce, hospitality and payments offerings, it is committed to serving businesses and individuals whose commercial activities involve cross-border transactions.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.